Form 4: Ovid Therapeutics COO Margaret Alexander Acquires 140,000 Employee Stock Options

Margaret A. Alexander, President and COO of Ovid Therapeutics, reports the acquisition of 140,000 employee stock options.

Summary

• On September 9, 2024, Margaret A. Alexander, the President and COO of Ovid Therapeutics Inc., acquired 140,000 employee stock options.
• The exercise price of these options is $1.07.
• These options vest over time, with 25% vesting on September 9, 2025, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• The options expire on September 8, 2034.
• Following this transaction, Alexander directly owns 140,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive due to the incentive structure.

Positives

• The granting of stock options to the COO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
• The vesting schedule encourages long-term commitment from the COO.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key executives. The vesting schedule is typical for aligning executive compensation with long-term company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize stock options with similar vesting schedules to incentivize their executives.
• The size of the grant is within the typical range for a COO position at a company of Ovid Therapeutics' size and stage.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the COO to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates